Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| KALA BIO Inc | KALA | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 6.7361 | 06:33:21 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 6.7361 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 5.10 - 16.84 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 6.7361 | USD |
KALA BIO Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 18.15M | 2.69M | - | 230k | -42.2M | -15.67 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
KALA BIO News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KALA Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 6.43 | 7.2321 | 6.07 | 6.66 | 15,286 | 0.3061 | 4.76% |
| 1 Month | 6.84 | 7.3004 | 6.07 | 6.54 | 28,887 | -0.1039 | -1.52% |
| 3 Months | 7.58 | 8.0929 | 6.07 | 6.93 | 17,783 | -0.8439 | -11.13% |
| 6 Months | 6.33 | 10.97 | 6.07 | 8.01 | 50,506 | 0.4061 | 6.42% |
| 1 Year | 16.77 | 16.84 | 5.10 | 10.10 | 43,148 | -10.03 | -59.83% |
| 3 Years | 295.50 | 338.50 | 3.5444 | 70.60 | 997,397 | -288.76 | -97.72% |
| 5 Years | 291.00 | 734.00 | 3.5444 | 210.54 | 1,086,575 | -284.26 | -97.69% |
KALA BIO Description
| Kala Pharmaceuticals Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY Mucus Penetrating Particles, technology, with an initial focus on the treatment of eye diseases. AMPPLIFY particles are selectively-sized nanoparticles and have proprietary coatings. It has applied the AMPPLIFY technology to create nanosuspensions of loteprednol etabonate, or LE, acorticosteroid designed for ocular applications, resulting in two product candidates. INVELTYS was approved in August 2018 for the treatment of inflammation and pain following ocular surgery and KPI-121 0.25 per cent is in Phase 3 development for the temporary relief of the signs and symptoms of dry eye disease. |
